patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Hub Home

> Log In

Demo Video
Private Messages
Edit My Profile
View/Edit Portfolio

Fast Facts

Name	Symbol	Exchange
Pluristem Life Systems, Inc.	PSTI	NAZ
Shares Outstanding	Financials	Industry
Issued: 6,750,698 shares	View Filings	Technology & Medical
Transfer Agent		Website
Nevada Agency & Trust Company		http://www.pluristem.com

Last changed at 22-Feb-2009 11:02AM by emit

Recent Updates

Press Release - Nov 17, 09 08:18AM

NEWS!! 3 mnth patient follow-up data re patient receiving PLX-PAD!!!

Press Release - Oct 21, 09 08:16AM

NEWS: Pluristem Therapeutics Will Chair a Panel Presentation on Placenta-Derived

WebLink - Oct 13, 09 07:48PM

9-10-09, Pluristem Begins Enrollment in U.S. in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease.

Press Release - Sep 23, 09 08:08AM

NEWS this am: PSTI Doses First Patient in U.S. With Placenta-Derived Stem Cell

Press Release - Sep 10, 09 02:10PM

NEWS this AM /PSTI Begins Enrollment in U.S. for Phase I Trial for PAD

Top Rated Messages

Sorry, no rated messages found

See more top rated messages

Most Recent Messages

EDIGOKIE..at least we win 2 ways with this one..I have a special interest in		emma Nov 19, 09 08:10AM
Re: NEWS!! 3 mnth patient follow-up data re patient receiving PLX-PAD!!!		EDIGOKIE Nov 18, 09 02:57PM
NEWS!! 3 mnth patient follow-up data re patient receiving PLX-PAD!!!		emma Nov 17, 09 08:18AM
Re: Hellooo!! Anyone see SEC dc. filed 11/10/09:		danr1 Nov 11, 09 08:58PM
Re: Hellooo!! Anyone see it?		danr1 Nov 11, 09 08:50PM

Go to Full Discussion Forum

AGORACOM Quick Tips

What Junior Gold Producer just reported $6.1 Million in Quarterly Profits? Find Out Now

Click To Watch Today's Show

President's D.D.

9-10-09, Pluristem Begins Enrollment in U.S. in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease.

It has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD for the treatment of critical limb ischemia, of (PAD). read more